semaglutide small dose Higher dose of semaglutide increases

PLoS One 9:e103443

This distinction matters because the level of oversight varies significantly between these facility types

Serious injuries and symptoms discussed in Wegovy and GLP-1 litigation may include: Gastroparesis or delayed gastric emptying Stomach paralysis symptoms, including nausea, vomiting, bloating, abdominal pain, early fullness, and difficulty keeping food down Ileus or intestinal blockage Bowel obstruction or pseudo-obstruction Persistent vomiting and dehydration Malnutrition or inability to tolerate normal food intake Severe abdominal pain requiring emergency care or hospitalization Pancreatitis, which has been reported as a risk signal in GLP-1 research NAION-related vision loss, which should be evaluated separately from gastrointestinal injury claims These allegations do not mean every patient who used Wegovy has a claim

Researchers have also identified a protein it makes, called P9, that stimulates GLP-1 release in laboratory and animal studies

it is 14 state Blue Cross plans under the Elevance Health corporate parent, each with state-specific formulary and contract rules Most Anthem fully insured commercial plans cover Wegovy with prior authorization, but self-funded employer plans frequently exclude it CarelonRx, Anthem's in-house PBM, took over pharmacy administration for most Anthem plans in 2024, changing prior authorization workflows The March 2024 FDA cardiovascular indication added a coverage pathway for members with established heart disease State Medicaid managed care plans administered by Anthem follow state Medicaid formulary rules, not Anthem's commercial formulary Direct answer Many Anthem commercial plans cover Wegovy with prior authorization as of May 2026, but coverage varies significantly across Anthem's 14-state footprint, individual employer contracts, and Medicaid managed care plans